Human Breast Cell SK-BR-3 based Proliferation Assay Service
Creative Biolabs' solutions are specifically designed to address the complexity of human epidermal growth factor receptor 2 (HER2)-driven cancers and next-generation therapeutics, particularly antibody-drug conjugates (ADCs). We understand that HER2 expression is highly heterogeneous, impacting both diagnosis and treatment efficacy. Our comprehensive service package is engineered to provide robust, high-quality data on target binding, receptor dimerization, and downstream signaling. This focus on mechanistic detail ensures the generated data package is reliable, clinically relevant, and robust enough to support the clinical translation of your HER2-targeting therapeutic.
The Significance of the SK-BR-3 Cell Line
The SK-BR-3 cell line is a vital benchmark in HER2 oncology research, defined by dramatic HER2/neu receptor overexpression, which mirrors 20% of human breast cancers. This clinical relevance makes it an ideal platform for highly accurate in vitro prediction of drug efficacy against this aggressive subtype. Its model consistency ensures reliable data, while its established use for modeling drug resistance makes it superior for studying drug failure mechanisms. Furthermore, its pathway specificity provides the ideal system for evaluating targeted agents blocking HER2 dimerization or inhibiting critical downstream cascades (e.g., PI3K/AKT/mTOR).
How Creative Biolabs' Proliferation Assay Can Assist Your Project
Quantitative Potency Benchmarking
We accurately determine IC50 and EC50 values, providing the robust metrics necessary for competitive analysis and regulatory submissions, establishing your therapeutic's efficacy threshold.
Mechanism of Action Elucidation
We integrate the proliferation readout with advanced phenotyping to pinpoint critical pathway perturbations, validating your drug's target engagement on the SK-BR-3 model.
Modeling Drug Resistance
We employ established SK-BR-3 resistant models to evaluate your compound's effectiveness against therapy failure, which is critical for anticipating outcomes and accelerating the development of potent combination strategies.
Support for ADCs
Our high-sensitivity, low-concentration assay protocol is perfectly suited for characterizing the unique potency dynamics of ADCs, providing the meticulous analysis required for these highly potent therapies.
Ready to translate your drug candidate into actionable data? Discover How We Can Help - Request a Consultation today to scope your SK-BR-3 screening project.
Workflow: From Sample Submission to Mechanistic Insight
The end-to-end process at Creative Biolabs is designed for clarity, efficiency, and scientific rigor, providing a seamless path from candidate molecule to actionable data package. We prioritize transparency and clear communication at every stage of the study.
Publication
This study suggests that the opioid analgesic oxycodone (OXY) may enhance the anti-tumor efficacy of chemotherapy drug paclitaxel (PTX) in breast cancer SKBR3 cells. OXY alone inhibits proliferation, migration, and invasion. The combination significantly augments PTX-induced apoptosis. Mechanistically, OXY suppresses the PI3K/Akt/mTOR signaling pathway, inhibits epithelial-mesenchymal transition (EMT), and modulates autophagy. These findings propose a novel combined therapeutic strategy for breast cancer.
Fig.1 The impact of OXY alone and in combination with PTX on the viability and proliferation of SKBR3 cells. 1
Why Choose Us
Creative Biolabs is the partner of choice for leading biotech and pharmaceutical companies, leveraging decades of HER2 expertise and bioassay validation to accelerate regulatory filings. Our platform provides multi-modal data output, moving beyond basic proliferation by integrating high-content screening (HCS) and metabolic analysis for a holistic view of drug efficacy. We offer ADC optimization with a high-sensitivity, luminescence based method ideal for nanomolar potency. Every assay is performed under strict quality control standards for maximum reliability and reproducibility, assuring data integrity.
Experience the Creative Biolabs Advantage - Get a Quote Today to discuss how our platform can advance your HER2 oncology pipeline.
FAQs
Q1: How does the SK-BR-3 assay compare to using other HER2-positive lines like BT474?
A1: While BT474 is also useful, SK-BR-3 is often preferred for its distinct and robust HER2 overexpression profile, which facilitates the study of complex resistance mechanisms, as it shows a wider range of perturbed pathways. We recommend running both for comprehensive profiling.
Q2: Can you help us determine if our drug is cytostatic or cytotoxic?
A2: Yes, our real-time kinetic analysis allows us to track cell behavior over multiple days, providing definitive evidence on whether your compound merely inhibits growth (cytostatic) or actively kills cells (cytotoxic).
Q3: Our therapeutic strategy involves overcoming Trastuzumab resistance. Do you offer pre-established resistant SK-BR-3 models?
A3: Yes, we maintain and validate specific SK-BR-3 resistant sublines specifically for the mechanism of action and combination therapy studies. Utilizing these models allows you to directly assess your compound's ability to re-sensitize resistant cancer cells.
Customer Review
-
Unprecedented IC50 Resolution
Using Creative Biolabs' service in our research has significantly improved the resolution of our ADC IC50 values, especially at the ultra-low concentration end, allowing us to confidently distinguish subtle differences in conjugate potency. - Dr. La*Ga -
Efficiency Over MTT
The shift from our in-house MTT assay to Creative Biolabs' luminescence based kinetic readout has drastically reduced false positives and provided real-time kinetic growth data that is simply superior for characterizing cytostatic vs. cytotoxic effects. - Ms. Sy*Ms
Related Services
To fully accelerate your oncology program, clients often integrate the SK-BR-3 proliferation assay with complementary services offered by Creative Biolabs:
PBMC-mediated ADCC Assay Service
Creative Biolabs specializes in PBMC-mediated antibody-dependent cellular cytotoxicity (ADCC) assay services to accurately measure the cytotoxic potency of therapeutic antibodies. This assay is crucial for assessing immune-mediated killing and predicting antibody based treatment efficacy.
Learn More →Bispecific Antibody Analysis
Creative Biolabs provides comprehensive analysis for bispecific antibodies (BsAb) development, including biochemistry characterization, stability analysis, functional analysis, and PK/PD analysis.
Learn More →Contact Us
Creative Biolabs is your expert partner for preclinical HER2 oncology research. Our human breast cell SK-BR-3 based proliferation assay service delivers high-resolution potency data, critical mechanistic insight, and the reliable quality needed to confidently advance your drug candidates. We provide the complete data package for your crucial decision points.
Maximize your research budget and efficiency by bundling your SK-BR-3 proliferation assay with a complementary service. Request a combined quote today for a seamless research pathway.
Reference
- Liu, Fangfang, et al. "Oxycodone enhances antitumor effect of paclitaxel on human breast cancer SKBR3 cells in vitro." Clinics 79 (2024): 100458. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.clinsp.2024.100458
Download our brochure